Lucio Tentori Selected Research

GPI 15427

8/2006	Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
2/2005	Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
11/2003	Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lucio Tentori Research Topics

Disease

28	Neoplasms (Cancer) 01/2020 - 03/2002
20	Melanoma (Melanoma, Malignant) 01/2022 - 07/2002
5	Glioma (Gliomas) 01/2018 - 07/2002
5	Glioblastoma (Glioblastoma Multiforme) 10/2017 - 10/2002
4	Leukemia 01/2018 - 07/2002
4	Colonic Neoplasms (Colon Cancer) 07/2013 - 08/2006
4	Brain Neoplasms (Brain Tumor) 07/2005 - 07/2002
4	Lymphoma (Lymphomas) 02/2005 - 03/2002
3	Neoplasm Metastasis (Metastasis) 12/2005 - 07/2002
2	Prostatic Neoplasms (Prostate Cancer) 11/2018 - 05/2007
2	Colorectal Neoplasms (Colorectal Cancer) 07/2013 - 08/2006
2	Carcinoma (Carcinomatosis) 07/2013 - 08/2006
2	Inflammation (Inflammations) 06/2008 - 08/2006
2	Breast Neoplasms (Breast Cancer) 01/2007 - 07/2003
2	Genomic Instability 02/2006 - 07/2005
2	Experimental Melanoma 12/2005 - 02/2005
2	Necrosis 02/2005 - 02/2002
2	Adenocarcinoma 07/2003 - 03/2002
1	Pathologic Neovascularization 01/2020
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 09/2019
1	Disease Progression 11/2016
1	Urinary Bladder Neoplasms (Bladder Cancer) 11/2016
1	Carcinogenesis 05/2007
1	Diarrhea 08/2006

Drug/Important Bio-Agent (IBA)

14	Temozolomide (Temodar)FDA LinkGeneric 03/2014 - 03/2002
11	Poly(ADP-ribose) Polymerase InhibitorsIBA 09/2019 - 03/2002
8	Pharmaceutical PreparationsIBA 01/2020 - 07/2002
7	Monoclonal AntibodiesIBA 01/2022 - 01/2012
7	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 09/2019 - 01/2003
6	D16F7IBA 01/2020 - 11/2016
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 03/2004
6	Poly (ADP-Ribose) Polymerase-1IBA 03/2014 - 03/2002
5	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2020 - 11/2016
5	Antineoplastic Agents (Antineoplastics)IBA 01/2009 - 03/2002
4	Proteins (Proteins, Gene)FDA Link 05/2015 - 02/2006
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
3	IpilimumabIBA 01/2022 - 01/2012
3	LigandsIBA 05/2018 - 11/2016
3	Dacarbazine (DIC)FDA LinkGeneric 05/2011 - 03/2004
3	O-(6)-methylguanineIBA 01/2009 - 07/2002
3	GPI 15427IBA 08/2006 - 11/2003
3	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2003 - 03/2002
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 01/2018
2	VemurafenibIBA 01/2020 - 05/2015
2	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2019 - 05/2011
2	MC3181IBA 01/2019 - 05/2015
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018 - 05/2007
2	JNK Mitogen-Activated Protein KinasesIBA 05/2015 - 05/2011
2	CilengitideIBA 03/2015 - 04/2008
2	IntegrinsIBA 03/2015 - 04/2008
2	Irinotecan (Camptosar)FDA LinkGeneric 07/2013 - 08/2006
2	Complementary DNA (cDNA)IBA 07/2013 - 07/2013
2	Hormones (Hormone)IBA 05/2007 - 02/2006
2	Corticotropin-Releasing HormoneIBA 01/2007 - 02/2006
2	Estrogens (Estrogen)FDA Link 01/2007 - 07/2003
2	Topoisomerase I InhibitorsIBA 08/2006 - 07/2005
2	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 08/2006 - 02/2005
2	EnzymesIBA 07/2005 - 01/2003
2	methyl lexitropsinIBA 02/2005 - 03/2002
2	N3-methyladenineIBA 02/2005 - 07/2002
2	A-Form DNA (A-DNA)IBA 11/2003 - 03/2002
2	Drug CombinationsIBA 10/2002 - 03/2002
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	NivolumabIBA 01/2022
1	Placenta Growth FactorIBA 01/2020
1	Vascular Endothelial Growth Factor BIBA 01/2020
1	olaparibIBA 09/2019
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019
1	gamma-glutamylaminomethylsulfonic acid (GAMS)IBA 01/2017
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 11/2016
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 11/2016
1	Ellagic AcidIBA 11/2016
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 11/2016
1	Ethanol (Ethyl Alcohol)IBA 05/2015
1	Mitogen-Activated Protein KinasesIBA 05/2015
1	Metalloproteases (Metalloproteinases)IBA 03/2015
1	matrigelIBA 03/2015
1	Neuropilin-1IBA 03/2015
1	platelet-derived growth factor C (PDGF-C)IBA 12/2013
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2013
1	Platinum Compounds (Compounds, Platinum)IBA 07/2013
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 07/2013
1	Glutathione S-Transferase piIBA 05/2011
1	6- (7- nitro- 2,1,3- benzoxadiazol- 4- ylthio)hexanolIBA 05/2011
1	DNA alkyltransferaseIBA 01/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2008
1	cyclic arginine-glycine-aspartic acid peptideIBA 04/2008
1	Erythropoietin FDA Link 05/2007
1	Anabolic Androgenic SteroidsIBA 05/2007
1	Insulin (Novolin)FDA Link 05/2007
1	Growth Hormone (Somatotropin)IBA 05/2007
1	Illicit Drugs (Recreational Drugs)IBA 05/2007
1	Insulin-Like Growth Factor I (IGF-1)IBA 05/2007
1	Messenger RNA (mRNA)IBA 01/2007
1	Bleomycin (Blenoxane)FDA LinkGeneric 02/2006

Therapy/Procedure

15	Therapeutics 09/2019 - 01/2003
9	Drug Therapy (Chemotherapy) 11/2018 - 07/2002
2	Oral Administration 11/2018 - 08/2006
1	Immunotherapy 01/2020
1	Radiotherapy 01/2009